Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome

Author(s):  
A Otto Quartero ◽  
Villy Meiniche-Schmidt ◽  
Jean Muris ◽  
Gregory Rubin ◽  
Niek de Wit
1988 ◽  
Vol 81 (12) ◽  
pp. 718-720 ◽  
Author(s):  
D Waxman

The irritable bowel syndrome is discussed together with some of its theories, methods of investigation and various treatment regimens. Eight case histories are reported. In each patient, symptoms appeared to be precipitated by situations interpreted by that patient as stressful. A programme of prospective desensitization using hypnosis is described. Where symptoms of depression were additionally present, antidepressant medication was prescribed. This was subsequently phased out as and when indicated. Where patients had been taking antidiarrhoeal or antispasmodic drugs, various stool bulking agents or benzodiazepines, these were also slowly discontinued as treatment progressed. Cases were followed up from 3 months to 12 years. In 2 cases recurrence of symptoms was again successfully treated. There was no recurrence of any of the bowel symptoms in any other patient. The results support the view that the irritable bowel syndrome is psychogenic in origin.


2002 ◽  
Author(s):  
AO Quartero ◽  
V Meiniche-Schmidt ◽  
J Muris ◽  
J Neeleman ◽  
G Rubin ◽  
...  

2007 ◽  
Vol 21 (suppl b) ◽  
pp. 3B-22B ◽  
Author(s):  
Pierre Paré ◽  
Ronald Bridges ◽  
Malcolm C Champion ◽  
Subhas C Ganguli ◽  
James R Gray ◽  
...  

While chronic constipation (CC) has a high prevalence in primary care, there are no existing treatment recommendations to guide health care professionals. To address this, a consensus group of 10 gastroenterologists was formed to develop treatment recommendations. Although constipation may occur as a result of organic disease, the present paper addresses only the management of primary CC or constipation associated with irritable bowel syndrome. The final consensus group was assembled and the recommendations were created following the exact process outlined by the Canadian Association of Gastroenterology for the following areas: epidemiology, quality of life and threshold for treatment; definitions and diagnostic criteria; lifestyle changes; bulking agents and stool softeners; osmotic agents; prokinetics; stimulant laxatives; suppositories; enemas; other drugs; biofeedback and behavioural approaches; surgery; and probiotics. A treatment algorithm was developed by the group for CC and constipation associated with irritable bowel syndrome. Where possible, an evidence-based approach and expert opinions were used to develop the statements in areas with insufficient evidence. The nature of the underlying pathophysiology for constipation is often unclear, and it can be tricky for physicians to decide on an appropriate treatment strategy for the individual patient. The myriad of treatment options available to Canadian physicians can be confusing; thus, the main aim of the recommendations and treatment algorithm is to optimize the approach in clinical care based on available evidence.


2020 ◽  
Vol 13 ◽  
pp. 175628482091063
Author(s):  
Maite Casado-Bedmar ◽  
Åsa V. Keita

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder characterized by recurring abdominal pain and disturbed bowel habits. The aetiology of IBS is unknown but there is evidence that genetic, environmental and immunological factors together contribute to the development of the disease. Current treatment of IBS includes lifestyle and dietary interventions, laxatives or antimotility drugs, probiotics, antispasmodics and antidepressant medication. The gut–brain axis comprises the central nervous system, the hypothalamic pituitary axis, the autonomic nervous system and the enteric nervous system. Within the intestinal mucosa there are close connections between immune cells and nerve fibres of the enteric nervous system, and signalling between, for example, mast cells and nerves has shown to be of great importance during GI disorders such as IBS. Communication between the gut and the brain is most importantly routed via the vagus nerve, where signals are transmitted by neuropeptides. It is evident that IBS is a disease of a gut–brain axis dysregulation, involving altered signalling between immune cells and neurotransmitters. In this review, we analyse the most novel and distinct neuro-immune interactions within the IBS mucosa in association with already existing and potential therapeutic targets.


1998 ◽  
Vol 3 (3) ◽  
pp. 106-107
Author(s):  
Sonia Gwilliam ◽  
F Ledwith

In a recent review in The Lancet, it was suggested that, with regard to irritable bowel syndrome (IBS), "there is no easy treatment ... and no cure". Naturopathic therapists, however, report high levels of success in the longterm alleviation of the condition using whole vegetable fibre, but not bran which is "the wrong kind of fibre". As a straw poll, preliminary interviews carried out by one of the authors (SG) with three medical practitioners (two GPs and a consultant enterologist) and three naturopathic healers indicated wide differences in approaches to treatment and expectations of success. The medical practitioner mainly mentioned anti-spasmodic drugs, bulking agents and possibly mild anti-depressants, but expressed distinct lack of confidence that anything would be very effective. The naturopaths stressed dietary change, mainly centring around eating raw food, as the main treatment, and expressed confidence as to outcome, based on the experience of consultations with up to ten clients per week. When asked about the value of raw food, generally the medical practitioner did not understand the question, so the meaning of the term had to be explained. When asked about how fibre might be increased, their suggestions were fairly non-specific: for example, certain breakfast cereal and "fruit and veg". It seems likely, therefore, that patients consulting their doctors would not get advice on diet which naturopaths believe would be effective.


2000 ◽  
Vol 118 (4) ◽  
pp. A1199
Author(s):  
Lloyd R. Sutherland ◽  
Eldon A. Shaffer ◽  
Duncan R. MacCannell

Author(s):  
Lisa Ruepert ◽  
A Otto Quartero ◽  
Niek J de Wit ◽  
Geert J van der Heijden ◽  
Gregory Rubin ◽  
...  

Author(s):  
Gupta Bikash ◽  
Dash Biswajit ◽  
Paul Sujata ◽  
Bora Jyoti Aditya

Irritable bowel syndrome (IBS) is a gastrointestinal disease which is also called as spastic colon, mucous colitis is characterized by some non-specific symptoms, such as altered bowel habits and abdominal pain, stomach bloating, chronic diarrhea or constipation or alternating between the two. The therapy is based on the healing of symptoms using various pharmaceutical and non-pharmaceutical agents. The objective of treatment is relief from symptom and improved quality of life. The approach for the treatment of IBS is based on the predominant symptoms of the patient. Classical as well as alternative treatment, both appear to be effective for the patients. Classical treatments basically consist of antidiarrheal, antidepressants, antispasmodic, bulking agents, osmotic laxatives, etc. Still, herbal or alternative treatment always seems to be the same beneficiary for the patients due to their negligible adverse effect.


Sign in / Sign up

Export Citation Format

Share Document